Altimmune to Participate in the Citizens Life Sciences Conference
Rhea-AI Summary
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.
Positive
- Late clinical-stage company status indicates advanced product development pipeline
Negative
- None.
News Market Reaction – ALT
On the day this news was published, ALT gained 2.94%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
| Conference: | Citizens Life Sciences Conference |
| Date/Time: | Wednesday, May 7, 2025, at 9:30 a.m. EDT |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jason Spark
Inizio Evoke, Biotech
Phone: 619-849-6005
Jason.spark@canalecomm.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the Citizens Life Sciences Conference 2025?
How can investors watch Altimmune's (ALT) Citizens Life Sciences Conference presentation?
What type of company is Altimmune (ALT) in 2025?
Where is the Citizens Life Sciences Conference 2025 with Altimmune (ALT) being held?
What format will Altimmune's (ALT) presentation take at the May 2025 Citizens conference?
